HCW Biologics is trading 10.9% down today at $2.30 following the announcement of a $1.6 million private placement of stock and warrants with accredited investors.
- The financing is expected to dilute existing shareholders, a move that often triggers negative sentiment for small-cap equities in a risk-off market.
- The company plans to utilize the proceeds for working capital, general corporate purposes, and the continued advancement of its clinical development programs.